Samsung’s Life Science Fund to invest in US AAC capsids co. – Pulse by Maeil Business News Korea – Pulse News

Samsung C&T Corp., Samsung Biologics Co. and Samsung Bioepis Co. will invest in Latus Bio, Inc., a U.S. gene therapy development company, through their “Life Science Fund,” the South Korean Samsung Group companies announced Friday .

Latus Bio has technology that screens and verifies adeno-associated virus (AAV) capsids, which selectively act on central nervous system disorders. AAV is used to develop drugs that deliver therapeutic genes into the body to treat congenital genetic diseases.

Latus Bio has discovered novel AAV capsids for brain tissue penetration based on its capsid engineering platform and has several gene therapy pipelines (products in development) for brain neurological diseases, according to Samsung Biologics.

“Discovering capsids with excellent brain tissue selectivity is a major challenge in AAV technology,” said Cho Ho-sung, executive vice president and head of early-stage research and development at Samsung Bioepis. “Latus Bio is a company with high expertise and growth potential in the field of AAV.”

The Life Sciences Fund is a venture capital investment fund jointly formed by Samsung C&T, Samsung Biologics and Samsung Bioepis, and is managed by Samsung Venture Investment Corp. The fund invested in the American gene therapy development company Jaguar Gene Therapy, LLC, an American nanoparticle-based drug. delivery systems developer Senda Biosciences, Inc., Swiss antibody-drug conjugate (ADC) technology developer Araris Biotech AG, Korean ADC developer Aimed Bio Inc., and U.S. ADC-related biotechnology company BrickBio , Inc.

By impulse

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]